Hiroko Otsuka, Yoshitaka Gotoh, Takashi Komeno, Takahide Ono, Yasushi Kawasaki, Naoyuki Iida, Yoshio Shibagaki, Seisuke Hattori, Makoto Tomatsu, Hirotada Akiyama, Fumio Tashiro
Biochemical and biophysical research communications 2014 Oct 10Aralin from Aralia elata is a newly identified type II ribosome- inactivating protein, which preferentially induces apoptosis in cancer cells. In this study, we identified that the aralin receptor is a 110-kDa high-density lipoprotein-binding protein (HDLBP), which functions as a HDL receptor. The sensitivities of tumor cell lines to aralin were dependent on the expression levels of the 110-kDa HDLBP and its forced expression in aralin-resistant Huh7 cells conferred aralin sensitivity. HDLBP-knockdown HeLa cells showed a significant aralin resistance in vitro and in vivo. Conversely, ectopic expression of the 150-kDa HDLBP resulted in increased aralin sensitivity in vivo, accompanying enhanced expression of the 110-kDa HDLBP. Thus, these results showed that the 110-kDa HDLBP in lipid rafts acted as an aralin receptor and that its expression levels determined aralin sensitivity, suggesting that aralin could be a promising anticancer drug for HDLBP-overexpressing tumors. Copyright © 2014 Elsevier Inc. All rights reserved.
Hiroko Otsuka, Yoshitaka Gotoh, Takashi Komeno, Takahide Ono, Yasushi Kawasaki, Naoyuki Iida, Yoshio Shibagaki, Seisuke Hattori, Makoto Tomatsu, Hirotada Akiyama, Fumio Tashiro. Aralin, a type II ribosome-inactivating protein from Aralia elata, exhibits selective anticancer activity through the processed form of a 110-kDa high-density lipoprotein-binding protein: a promising anticancer drug. Biochemical and biophysical research communications. 2014 Oct 10;453(1):117-23
PMID: 25261720
View Full Text